AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05970497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdualag
Description: Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
Study NCT04717479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
Study NCT04889365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SG Diagnostics COVID-19 Antigen Rapid Test Kit
Description: SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
Study NCT04868396 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
Study NCT04889365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction (PCR) test
Description: Professional collection of a second swab sample, for confirmation by PCR
Study NCT06357416 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MV-POCT Sub-study
Description: Point of care blood testing
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Main Man Van Group Sub-study (MV-Eco)
Description: Consent for long-term follow-up of patients
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MV-QualQ Sub-study
Description: Qualitative questionnaire and interview sub-study
Study NCT06570915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
Study NCT06523426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patient treated by spinal endoscopy
Description: Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
Study NCT05520619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
Study NCT05520619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
Study NCT05741034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLITE™
Description: Injection, subdermal and/or intradermal
Study NCT05741034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No-treatment control
Study NCT05175352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified dose on specified days
Study NCT05175352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP substrates
Description: Specified dose on specified days
Study NCT06357416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MV-PRS Sub-study
Description: Patients consenting to polygenic risk score testing
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MV-DNA and MV-UctDNA Sub-study
Description: Patients consenting to collection of DNA and urine for further study.
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MV-SSI Sub-study
Description: Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
Study NCT06357416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MV-TPP Sub-study
Description: Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
Study NCT05921812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: real time pcr
Description: evaluate the expression of certain circulating microRNAs by real time pcr
Study NCT06127771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programming DBS using Percept PC neurostimulator's full potential
Description: This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
Study NCT04236947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCPP-YA
Description: SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
Study NCT06286657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
Study NCT06286657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Study NCT05391828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design
Description: TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
Study NCT05391828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design
Description: TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
Study NCT06605677 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
Study NCT06543381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06543381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given PO
Study NCT04875533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC
Study NCT04875533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline
Study NCT04875533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study NCT04875533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study NCT05298384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression stockings
Description: Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
Study NCT05324982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be orally self-administered by study participants.
Study NCT05324982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBG Cannabis
Description: CBG cannabis oil will be orally self-administered by study participants.
Study NCT06426771 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary Inflammatory Index
Description: The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of >3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
Study NCT06426771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hormone profile
Description: In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
Study NCT06615596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discontinue anticoagulation therapy
Description: Participants in the discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
Study NCT06615596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant drugs
Description: Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
Study NCT06615596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
Study NCT06615596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
Study NCT04715178 — intervention group
Intervention type: OTHER
Intervention: No intervention- registry only
Description: No intervention- registry only
Study NCT06668480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors
Study NCT06668480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening Exercise
Description: Strengthening exercises of lower fibers of trapezius
Study NCT06668480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNAG'S
Description: Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks
Study NCT06615687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted T shape Free Gingival Graft
Description: the preparation of the recipient site commenced by making a horizontal incision at the mucogingival junction (MGJ) as well as two vertical incisions extending to the adjacent teeth and about 3-4 mm beyond the MGJ. A sharp split-thickness flap will be reflected, and the surfaces between these incisions will be de-epithelialized. Also, all the surfaces of the interdental papilla up to the lingual side will be de-epithelized using a 15c blade and microsurgical scissor .(Harvesting of the palatal donor site will be designed 2 mm away from the gingival margin using a template in the form of an inverted T-shape, taking into consideration the position of the greater palatine blood vessels at 5 mm. 2 mm is required for the width of the interproximal extension with 3 mm length to obtain an even thickness of 1-1.5 mm .~Placement of the graft : The Inverted T FGG will be inserted between the teeth to cover interproximal tissue defect and sutured lingually into the lingual marginal gingiva
Study NCT06615687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Preparation of the recipient site :Following an intrasulcular incision, 2 mm-long horizontal incisions at the level of the CEJ will be performed bilaterally. From these, vertical releasing incisions will be placed in a diverging manner, extending well into the alveolar mucosa, a thin partial thickness flap will be subsequently raised then excised. The dimension of the resulting site will be measured to obtain a rectangular foil template .~Harvesting of the Graft :Using the foil template, graft dimensions will be outlined in the palate adjacent to the premolars and first molar. A partial thickness graft consisting of epithelium and a thin layer of underlying connective tissue will be harvested (intended total thickness of graft: 1.5 mm), maintaining a distance of ≥2 mm to the maxillary teeth.
Study NCT06617962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBA method of live cells and fixed cells
Description: 1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples.
Study NCT06614335 — intervention group
Intervention type: OTHER
Intervention: After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation
Description: All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.
Study NCT05520619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
Study NCT04861051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Study participants will receive 0.5mg/kg of ketamine - one single infusion
Study NCT06692985 — intervention group
Intervention type: OTHER
Intervention: Clinical and epidemiological data
Description: Collection of clinical and epidemiological data on day 0
Study NCT06692985 — intervention group
Intervention type: OTHER
Intervention: Parasitological samples
Description: Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0
Study NCT06692985 — intervention group
Intervention type: OTHER
Intervention: Assessment of clinical course and response to treatment
Description: Follow-up visit with assessment of clinical course and response to treatment at M6
Study NCT06692985 — intervention group
Intervention type: OTHER
Intervention: DLQI questionnaire
Description: DLQI questionnaire at M6
Study NCT05513235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital personal health record
Description: The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
Study NCT06682117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons.
Study NCT06137755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-VZV-001
Description: Investigational Product
Study NCT06137755 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Investigational Product
Study NCT06697561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education program
Description: The intervention for the experimental group was an evidence-based educational program for hand dysfunction in patients with systemic sclerosis, which included a health education manual and multimedia videos developed through evidence translation. Additionally, individual education and consultation were provided.
Study NCT06632262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061 + ABSK043
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Study NCT06632262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061+ABSK043 in combination with CAPOX
Description: Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Study NCT06696989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frenkel's exercises
Description: In this group, participants will receive Frenkel's exercises, and the total treatment session will be 60 minutes of routine physical therapy, i.e., breathing, stretching, ROM's, and joint mobility, with rest intervals in between for 20 minutes. To begin the intervention, the investigator will perform Frenkel's exercises for 40 minutes in total, with rest intervals between each exercise, initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively, after 2 weeks.